Buscar
InMed Pharmaceuticals Inc
INMAñadir a la lista de seguimiento
1.460USD
-0.040-2.67%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
4.09MCap. mercado
PérdidaP/E TTM
Más Datos de InMed Pharmaceuticals Inc Compañía
InMed Pharmaceuticals Inc. is a pharmaceutical company. The Company develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
Información de InMed Pharmaceuticals Inc
Símbolo de cotizaciónINM
Nombre de la empresaInMed Pharmaceuticals Inc
Fecha de salida a bolsaJun 21, 2001
Director ejecutivoAdams (Eric A)
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 21
Dirección1445-885 West Georgia St.
CiudadVANCOUVER
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísCanada
Código postalV6C 3E8
Teléfono16046697207
Sitio Webhttps://www.inmedpharma.com/
Símbolo de cotizaciónINM
Fecha de salida a bolsaJun 21, 2001
Director ejecutivoAdams (Eric A)
Ejecutivos de InMed Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Andrew Harold Hull
Mr. Andrew Harold Hull
Independent Chairman of the Board
Independent Chairman of the Board
1.91K
--
Dr. Eric Chih-Hsien Hsu, Ph.D.
Dr. Eric Chih-Hsien Hsu, Ph.D.
Senior Vice President - Preclinical Research and Development
Senior Vice President - Preclinical Research and Development
2.00
--
Mr. Michael Henry Woudenberg
Mr. Michael Henry Woudenberg
Chief Operating Officer
Chief Operating Officer
1.00
--
Mr. Eric A. Adams
Mr. Eric A. Adams
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Colin Clancy
Mr. Colin Clancy
Vice President, Investor Relations and Corporate Communications
Vice President, Investor Relations and Corporate Communications
--
--
Mr. Bryan T. Baldasare
Mr. Bryan T. Baldasare
Independent Director
Independent Director
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
-100.00%
Ms. N. Netta (Neeta) Jagpal, CPA
Ms. N. Netta (Neeta) Jagpal, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Neil A. Klompas, CPA
Mr. Neil A. Klompas, CPA
Independent Director
Independent Director
--
--
Mr. John Bathery
Mr. John Bathery
Director
Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Andrew Harold Hull
Mr. Andrew Harold Hull
Independent Chairman of the Board
Independent Chairman of the Board
1.91K
--
Dr. Eric Chih-Hsien Hsu, Ph.D.
Dr. Eric Chih-Hsien Hsu, Ph.D.
Senior Vice President - Preclinical Research and Development
Senior Vice President - Preclinical Research and Development
2.00
--
Mr. Michael Henry Woudenberg
Mr. Michael Henry Woudenberg
Chief Operating Officer
Chief Operating Officer
1.00
--
Mr. Eric A. Adams
Mr. Eric A. Adams
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Colin Clancy
Mr. Colin Clancy
Vice President, Investor Relations and Corporate Communications
Vice President, Investor Relations and Corporate Communications
--
--
Mr. Bryan T. Baldasare
Mr. Bryan T. Baldasare
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de InMed Pharmaceuticals Inc?
Los cinco principales accionistas de InMed Pharmaceuticals Inc son: Mr. Andrew Harold Hull
¿Cuántas instituciones poseen acciones de InMed Pharmaceuticals Inc (INM)?
A fecha de 2026Q1, 31 instituciones poseen acciones de InMed Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 320.11K, lo que representa el 9.66% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -43643.00.